In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $40.00. The company's shares closed last Friday at $6.85. According to TipRanks.com, Roy is a 5-star analyst with an average return of 20.6% and a 36.4% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc. Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $30.19, which is a 338.2% upside from current levels.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-receives-a-buy-from-jonestrading?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Actinium Pharmaceuticals Charts.
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Actinium Pharmaceuticals Charts.